Amylyx Pharmaceuticals, Inc. (AMLX) vs Regencell Bioscience Holdings Limited (RGC)

Amylyx Pharmaceuticals, Inc. and Regencell Bioscience Holdings Limited are both Drug Manufacturers Specialty & Generic companies. Amylyx Pharmaceuticals, Inc. is the larger, with a market value of $3.8B against $3.1B — 1.2× the size. Across the 7 metrics below, Regencell Bioscience Holdings Limited leads on 4 and Amylyx Pharmaceuticals, Inc. on 3.

Valuation

Metric AMLX RGC Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 37.53 n/m 2.25
P/B 13.71 n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m 0.19 12.29
EV/Sales 34.68 n/m 2.56
Earnings yield (4.85%) (16.69%) (2.99%)
Free cash flow yield (3.99%) 0.00% 0.00%

Profitability

Metric AMLX RGC Drug Manufacturers Specialty & Generic median
Gross margin (42.65%) — 53.94%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (74.73%) 0.00% (0.40%)
Return on assets (66.25%) 0.00% (3.32%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AMLX RGC Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (77.06%) — 10.01%
EPS growth (last fiscal year) 65.46% 17.24% —
Revenue growth, 5-year CAGR — — 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AMLX RGC Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.05
Current ratio 12.12 1.42 2.31
Net debt to EBITDA 2.00 1.33 0.85

Dividend

Metric AMLX RGC Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AMLX RGC Drug Manufacturers Specialty & Generic median
Market cap 3.78b 3.06b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack